2026-04-27T08:51:05Zhttps://riubu.ubu.es/oai/requestoai:riubu.ubu.es:10259/109202025-10-04T00:05:21Zcom_10259_4862com_10259_5086com_10259_2604col_10259_4863
Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay
Chromikova, Veronika
Tan, Jessica
Aslam, Sadaf
Rajabhathor, Arvind
Bermudez-Gonzalez, Maria
Ayllón Barasoain, Juan
Simon, Viviana
García Sastre, Adolfo
Salaun, Bruno
Nachbagauer, Raffael
Krammer, Florian
Influenza hemagglutinin
ADCC
ADCP
Effector functions
Stalk antibodies
The stalk of the influenza virus hemagglutinin (HA) is an attractive target for antibody-based universal influenza virus vaccine development. While antibodies that target this part of the virus can be neutralizing, it has been shown in recent years that Fc receptor-mediated effector functions are of significant importance for the protective effect of anti-stalk antibodies. Several assays to measure Fc-Fc receptor interaction-based effector functions like antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis exist, but they suffer from limitations such as low throughput and high run-to-run variability. Reporter assays for antibody-dependent cellular cytotoxicity based on reporter cells that express luciferase upon engagement of human FcγRIIIa with the Fc of antigen-bound antibodies have been developed as well. These reporter assays can be used in a higher throughput setting with limited run-to-run assay variability but since they express only one Fc receptor, their biological relevance is unclear. Here we optimized an antibody-dependent cellular cytotoxicity reporter assay to measure the activity of antibodies to the conserved stalk domain of H1 hemagglutinin. The assay was then correlated to a CD107a-based degranulation assay, and a strong and significant correlation could be observed. This data suggests that the FcγRIIIa-based reporter assay is a good substitute for functional assays, especially in settings where larger sample numbers need to be analyzed.
2025-10-03
2025-10-03
2020-02
info:eu-repo/semantics/article
0264-410X
https://hdl.handle.net/10259/10920
10.1016/j.vaccine.2020.01.008
1873-2518
eng
Vaccine. 2020, V. 8, n. 38, p.1953–1961
https://doi.org/10.1016/j.vaccine.2020.01.008
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Elsevier